In August, Merck announced increases to the catalog pricing on most of the vaccines in their portfolio. Please remember that CPP Buying Group members have 90 days advanced notice, so this new pricing doesn’t go into effect until November 10, 2022. Updated pricing sheets were sent out to all buying group members last week. If you missed them, please contact the CPP office at cpp@nationwidechildrens.org.

The CDC has published their recommendation for pediatric pneumococcal vaccination, which includes either Prevnar 13 (PCV13) or Merck’s Vaxneuvance (PCV15). This will signal the insurance companies to begin paying for Vaxneuvance when administered to patients at 2, 4, 6, and 12-15 months. We recommend reaching out to your major payers to make sure adequate payment is in place before incorporating a new vaccine into your schedule. The CPT code for Vaxneuvance (PCV15) is 90671.

CPP buying group members will have access to discounts on both Prevnar 13 and Vaxneuvance through our partnerships with Pfizer and Merck. If you have questions about the pricing and which option might make the most sense for your practice, please contact the CPP team and we can help with a financial analysis and make sure you are linked to the appropriate discounts to maximize your savings opportunities. 

Merck's Gardasil 9 Vials and Sanofi's Menactra, DT and Imogam have been removed from the Pricing Sheets.

Receive your vaccine rebates sooner by signing up to receive them electronically! No need to wait on the post office or hassle with cashing a paper check. Complete this ACH Authorization Form and email it to CPP at cpp@nationwidechildrens.org or fax it to 614-722-2149 and begin receiving electronic rebate payments with the next rebate cycle in October!